WO2023169554A8 - 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用 - Google Patents

甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用 Download PDF

Info

Publication number
WO2023169554A8
WO2023169554A8 PCT/CN2023/080740 CN2023080740W WO2023169554A8 WO 2023169554 A8 WO2023169554 A8 WO 2023169554A8 CN 2023080740 W CN2023080740 W CN 2023080740W WO 2023169554 A8 WO2023169554 A8 WO 2023169554A8
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitor
preparation
methionine adenosyltransferase
present application
method therefor
Prior art date
Application number
PCT/CN2023/080740
Other languages
English (en)
French (fr)
Other versions
WO2023169554A1 (zh
Inventor
董理进
易韬
胡凯
田林
张毅
唐元清
张晓东
唐军
Original Assignee
赛诺哈勃药业（成都）有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 赛诺哈勃药业（成都）有限公司 filed Critical 赛诺哈勃药业（成都）有限公司
Publication of WO2023169554A1 publication Critical patent/WO2023169554A1/zh
Publication of WO2023169554A8 publication Critical patent/WO2023169554A8/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本申请提供了一种甲硫氨酸腺苷转移酶抑制剂、包含其的药物组合物及应用。本申请的化合物具有优异的MAT2a酶抑制活性，同时对癌症细胞的生长具有优异的抑制作用，因此本申请的化合物可在MAT2a相关的癌症或肿瘤疾病中具有优异的治疗效果。
PCT/CN2023/080740 2022-03-11 2023-03-10 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用 WO2023169554A1 (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN202210236154.5 2022-03-11
CN202210236154 2022-03-11
CN202211172965.X 2022-09-26
CN202211172965 2022-09-26
CN202211445963.3 2022-11-18
CN202211445963 2022-11-18

Publications (2)

Publication Number Publication Date
WO2023169554A1 WO2023169554A1 (zh) 2023-09-14
WO2023169554A8 true WO2023169554A8 (zh) 2023-11-09

Family

ID=87936151

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/080740 WO2023169554A1 (zh) 2022-03-11 2023-03-10 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用

Country Status (2)

Country Link
TW (1) TW202342024A (zh)
WO (1) WO2023169554A1 (zh)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019191470A1 (en) * 2018-03-30 2019-10-03 Agios Pharmaceuticals, Inc. Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
PE20212303A1 (es) * 2018-12-27 2021-12-10 Les Laboratoires Servier Sas Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer
SI3902803T1 (sl) * 2018-12-27 2023-06-30 Les Laboratoires Servier Aza-heterobiciklični inhibitorji mat2a in postopki uporabe za zdravljenje raka
US20220251081A1 (en) * 2019-05-31 2022-08-11 Les Laboratoires Servier Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
WO2021139775A1 (zh) * 2020-01-10 2021-07-15 江苏先声药业有限公司 吡啶酮化合物及应用
WO2022052924A1 (zh) * 2020-09-11 2022-03-17 上海凌达生物医药有限公司 一类含氮稠环类化合物的制备方法和用途

Also Published As

Publication number Publication date
WO2023169554A1 (zh) 2023-09-14
TW202342024A (zh) 2023-11-01

Similar Documents

Publication Publication Date Title
MXPA06000302A (es) Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden.
UA81682C2 (en) Normal;heading 1;heading 2;PYRROLO[3,4-c]PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS
ATE200677T1 (de) Substituierte tetra- und pentapeptid hemmstoffe der farnesyl protein transferase
TW200505924A (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
HK1082663A1 (en) Extract with anti-tumor and anti-poisonous activity
MY124853A (en) 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives.
EP1529527A3 (en) Valproic acid for a combination treatment of human cancers, tumor metastasis and minimal residual disease
AU6229686A (en) Soluble phosphorylated glucan
WO2001030381A3 (de) Verwendung von csf-1-inhibitoren
YU44404A (sh) Postupak za identifikovanje ciljnih enzima tumora
WO2021021979A3 (en) Hdac6 inhibitors and uses thereof
WO2005014572A8 (en) Pyrimidylpyrrole derivatives active as kinase inhibitors
WO2022175746A8 (en) Tyk2 inhibitors and uses thereof
MX2023009011A (es) Inhibidor de cdk.
AU1976183A (en) N-(2-amino-3,5-dibromobenzyl)- trans-4-amino-cyclohexanol derivatives
WO2005027936A3 (en) Pharmaceutical compositions and therapeutical treatment with oligo-beta-(1, 3)-glucans
WO2023169554A8 (zh) 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用
WO1988008842A3 (fr) 2-ACYLPYRIDIN-alpha-(N)-HETARYLHYDRAZONES SUBSTITUEES ET MEDICAMENTS CONTENANT CELLES-CI
GEP20032996B (en) Combinations of Protein Farnesyltransferase and HMG CoA Reductase Inhibitors, Pharmaceutical Compositions and Methods for Treatment
WO2001064251A3 (en) Combination chemotherapy
WO2003047697A3 (en) Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer
WO1999056697A3 (en) Pharmaceutical composition
AU2021322255A8 (en) Use of dexpramipexole for the treatment of moderate to severe asthma
Lopez et al. Drug therapy of Aspergillus otitis externa
AU2001249267A1 (en) Methods and compositions for elucidating protein expression profiles in cells

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23766131

Country of ref document: EP

Kind code of ref document: A1